Developing a new vaccine platform for better COVID-19 protection
Official title: Characterization and optimization of single dose, thermostable and durable vaccine platform towards increased clinical acceptance
Funded at Schepens Eye Research Institute · NIH-10979335 · Data updated 2026-11-12
This study is working on a new type of vaccine called PARVAX that aims to give long-lasting protection against COVID-19 and possibly other viruses, like the flu, and they're looking for ways to make it even better and more affordable for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Schepens Eye Research Institute NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 23, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $668,569 |
| NIH project number | 1R01AI179898-01A1 |
| Project ID | NIH-10979335 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who are at risk for COVID-19 and other respiratory infections, particularly those who may benefit from enhanced vaccine options.
✕Less likely to help
Patients who are not at risk for COVID-19 or those who have already received effective vaccines may not receive additional benefits from this research.
What this research studies
This research focuses on creating and optimizing a novel genetic vaccine platform called PARVAX, which aims to provide durable and broad immunity against COVID-19 and potentially other pathogens. The researchers will investigate how the vaccine works and enhance its effectiveness through engineering approaches. They will also test the vaccine's ability to protect against influenza viruses in preclinical models. The goal is to develop a vaccine that is not only effective but also affordable and scalable for widespread use.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and accessible vaccine for COVID-19 and other infectious diseases.
How similar studies have gone: Other research has shown promise in developing novel vaccine platforms, indicating that this approach could lead to significant advancements in vaccine technology.
Where this research is happening
-
Schepens Eye Research Institute
Boston, United States Active
Researchers
- Principal investigator: Zabaleta, Nerea — Schepens Eye Research Institute
- Study coordinator: Zabaleta, Nerea
Related research
Other NIH-funded projects on the same topics.
-
Open, shareable OCT imaging data to speed eye disease research
A large NIH grant aims to create an open, fast way to export and share 3-D eye scans (OCT) from multiple clinics to help researchers develop better AI tools for diagnosing and tracking eye diseases.
-
How immune responses cause long-term eye damage after nitrogen mustard exposure
Researchers are looking at how immune cells lead to lasting cornea injury after sudden nitrogen mustard exposure to help people with mustard gas–related eye damage.
-
smartphones help kids see better in Africa
A smartphone-based tool helps children in Africa measure vision errors so they can get eyeglasses more easily.
-
Population-wide deep learning glaucoma screening Models
Aims to create AI eye-screening tools that work well for diverse populations so people can get easy glaucoma checks from primary care or pharmacies.
-
Immune factors driving long-term eye damage from nitrogen mustard exposure
A research project explores how immune responses contribute to chronic eye damage after nitrogen mustard exposure, aiming to improve care for people at risk.
-
Corneal Healing: How Epithelium and Stroma Talk to Prevent Scarring
A study exploring how the surface layer of the cornea and the underlying tissue communicate to control healing and scarring after an injury.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.